Home›Bile Acid Binding Resins›Bile Acid Binding Resins + Elafibranor

Does Bile Acid Binding Resins Interact with Elafibranor?

CDI records a moderate classification for Bile Acid Binding Resins and Elafibranor. The stored summary is: Bile acid sequestrants may reduce ELAFIBRANOR absorption and systemic exposure, decreasing efficacy. The mechanism involves interference with absorption and systemic exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity
Moderate
Elafibranor Class
Peroxisome Proliferator-activated Receptor Agonist
Management
Monitor for effects
Data Source
U.S. FDA via OpenFDA

Recorded Mechanism

Interference with absorption and systemic exposure

What To Tell Your Doctor or Pharmacist

If you are taking Bile Acid Binding Resins and your doctor is considering prescribing Elafibranor (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Bile Acid Binding Resins+💊 Elafibranor(Iqirvo)

Severity & Interaction Details

🟡
moderate
Be aware — moderate interaction
Documented interaction with manageable risk. May require dose adjustment or monitoring.
Severity scale
MinorContra
On record
Yes
Drug A class
—
Drug B class
Peroxisome Proliferator-activated Receptor Agonist
Source
NLP:elafibranor

What this means in plain English

Bile acid sequestrants may reduce ELAFIBRANOR absorption and systemic exposure, decreasing efficacy.

About Bile Acid Binding Resins and Elafibranor

Elafibranor is a Peroxisome Proliferator-activated Receptor Agonist. Elafibranor is also sold under the brand name Iqirvo.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:elafibranor

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Bile Acid Binding Resins and Elafibranor against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations